X4 Pharmaceuticals, Inc.

NasdaqCM:XFOR Stock Report

Market Cap: US$137.1m

X4 Pharmaceuticals Management

Management criteria checks 3/4

X4 Pharmaceuticals' CEO is Paula Ragan, appointed in Jul 2014, has a tenure of 10.42 years. total yearly compensation is $2.04M, comprised of 30.3% salary and 69.7% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth $799.00K. The average tenure of the management team and the board of directors is 3.7 years and 5.8 years respectively.

Key information

Paula Ragan

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage30.3%
CEO tenure10.4yrs
CEO ownership0.6%
Management average tenure3.7yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 02

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Apr 19
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

Oct 07
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals: Upcoming Catalysts

Sep 19

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

Jul 20

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16
How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

CEO Compensation Analysis

How has Paula Ragan's remuneration changed compared to X4 Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$17m

Jun 30 2024n/an/a

US$18m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$2mUS$620k

-US$101m

Sep 30 2023n/an/a

-US$111m

Jun 30 2023n/an/a

-US$131m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$4mUS$583k

-US$96m

Sep 30 2022n/an/a

-US$103m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$100m

Dec 31 2021US$2mUS$562k

-US$103m

Sep 30 2021n/an/a

-US$85m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$78m

Dec 31 2020US$3mUS$543k

-US$62m

Sep 30 2020n/an/a

-US$55m

Jun 30 2020n/an/a

-US$55m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$2mUS$492k

-US$53m

Sep 30 2019n/an/a

-US$55m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$40m

Dec 31 2018US$921kUS$380k

-US$36m

Compensation vs Market: Paula's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD646.54K).

Compensation vs Earnings: Paula's compensation has been consistent with company performance over the past year.

CEO

Paula Ragan (54 yo)

10.4yrs

Tenure

US$2,044,761

Compensation

Dr. Paula Ragan, Ph D., is Member of Advisory Board of Tippingpoint Biosciences, Inc. Dr. Ragan serves as an Independent Director of CAMP4 Therapeutics Corporation since May 2019. She is a Founder of X4 Ph...

Leadership Team

NamePositionTenureCompensationOwnership
Paula Ragan
CEO, President & Director10.4yrsUS$2.04m0.58%
$ 799.0k
Adam Mostafa
CFO, Treasurer & Corporate Secretary6.3yrsUS$1.15mno data
Christophe Arbet-Engels
Chief Medical Officer1.3yrsUS$1.64mno data
Richard Peters
Founderno datano datano data
Renato Skerlj
Founderno datano datano data
Keith Flaherty
Founder & Member of Corporate Advisory Boardno datano datano data
Mary DiBiase
Chief Operating Officer3.3yrsUS$1.84m0.27%
$ 363.4k
Arthur Taveras
Chief Scientific Officer4.1yrsno data0.23%
$ 311.9k
Robert Arbeit
Senior Vice President of Clinical Development and Translational Researchno datano datano data
Mark Baldry
Chief Commercial Officer2.1yrsno data0.028%
$ 39.0k

3.7yrs

Average Tenure

60yo

Average Age

Experienced Management: XFOR's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paula Ragan
CEO, President & Director10.4yrsUS$2.04m0.58%
$ 799.0k
Keith Flaherty
Founder & Member of Corporate Advisory Board8.7yrsno datano data
Michael Wyzga
Independent Chairman of the Board6.4yrsUS$199.34k0.045%
$ 61.6k
Gary Bridger
Director5.8yrsUS$147.05k0.030%
$ 41.5k
David W. McGirr
Independent Director7.3yrsUS$166.05k0.030%
$ 41.5k
Alison Lawton
Independent Director4.2yrsUS$154.55k0.030%
$ 41.5k
William Aliski
Independent Director5.3yrsUS$165.05k0.030%
$ 41.5k
Michael Vasconcelles
Member of Corporate Advisory Board8.7yrsno datano data
Robert Woods
Independent Director1.2yrsUS$91.83kno data
Murray Stewart
Director5.8yrsUS$90.08k0.086%
$ 117.8k
Francoise de Craecker
Independent Director3.2yrsUS$152.05k0.030%
$ 41.5k

5.8yrs

Average Tenure

62yo

Average Age

Experienced Board: XFOR's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 20:29
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leah Rush CannBrookline Capital Markets
Arlinda LeeCanaccord Genuity
Kristen KluskaCantor Fitzgerald & Co.